Melanoma is an aggressive type of cancer for which treatment has dramatically evolved during the last 15 years, improving response and survival figures. This book, written by a diverse panel of experts, presents a description of the most relevant aspects of the epidemiology, diagnosis, local treatment, prognostic biomarkers and treatment for advanced disease, including the most recent research on novel molecules that are either approved or are undergoing clinical development. It includes insights on such challenging topics as when immunotherapy should be started in BRAF mutant patients, or which is the most appropriate treatment algorithm in those cases, as well as how to handle difficult and poor-prognosis melanoma cases, such as patients with brain metastases or patients with the uveal disease.